The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response will provide $23 million for Merck to produce additional doses of its investigational Ebola vaccine over the next year as part of the international response to the outbreak in the Democratic Republic of the Congo, and for domestic biodefense preparedness. Health officials in the DRC have vaccinated more than 192,000 high-risk contacts of infected people with the investigational vaccine, which has shown effectiveness against Ebola. ASPR’s Biomedical Advanced Research and Development Authority continues to work with Merck to advance development of the vaccine for licensure by the Food and Drug Administration. 
 

Related News Articles

Headline
Patients receiving either of two investigational treatments for Ebola in the Democratic Republic of the Congo had a greater chance of survival than those…
Headline
One year after the Democratic Republic of the Congo declared an outbreak of Ebola, the outbreak continues in North Kivu and Ituri provinces, with 2,698 cases…
Headline
The Centers for Disease Control and Prevention is working with the U.S. Embassy in the Democratic Republic of the Congo to preposition staff in Goma to rapidly…
Headline
The World Health Organization today declared the Ebola virus disease outbreak in the Democratic Republic of the Congo a public health emergency of…
Headline
Two investigational Ebola treatments being used in the ongoing outbreak in the Democratic Republic of the Congo are effective in laboratory studies.
Headline
The Centers for Disease Control and Prevention today activated its Emergency Operations Center to support the interagency response to the Ebola outbreak in…